Pro-Abortion States Push Back Against FDA’s Mifepristone Review
Attorneys general from Massachusetts, California, New Jersey, and New York have filed a petition (PDF) urging the FDA to ease restrictions on the abortion pill mifepristone, just days after FDA Commissioner Marty Makary announced a safety review of the drug.
The petition does not explicitly demand the removal of the Risk Evaluation and Mitigation Strategy (REMS)—a set of safety protocols—but instead calls on the FDA to reevaluate existing data proving the drug’s safety over its 25 years on the market, according to The New York Times.
The move comes in response to a controversial report from the conservative Ethics and Public Policy Center (EPPC), which has raised unverified safety concerns about mifepristone. While the report cites insurance claims data, it lacks peer-reviewed validation, yet has gained traction among anti-abortion groups.
The petition aims to counter misinformation and reinforce mifepristone’s well-documented safety record. A source from the Massachusetts AG’s office confirmed the effort, though details remain confidential.
This clash highlights the ongoing political and legal battle over abortion access in the U.S., particularly since the overturning of Roe v. Wade. As the FDA re-examines mifepristone’s safety, pro-abortion states are pushing back to protect and expand access to the widely used medication.
Would you like any adjustments for tone or additional context?